Drug sensitivity test for recurrent or metastatic head and neck cancer
Part of Cancer clinical trials.
This trial uses a patient's own tumor cells grown in a lab to test which drugs are most likely to work against their cancer. It aims to help guide treatment choices for people with head and neck cancer that has come back or spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer that has come back or spread to other parts of the body.
- A sample of your tumor can be taken and grown in the lab for testing.
- You are generally well enough to walk and care for yourself (ECOG score 0-2).
- Your major organs (like bone marrow, liver, kidneys) are working well enough for standard cancer treatments.
- You are willing to sign a consent form and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a laboratory-grown mini-tumor (organoid) from your biopsy can predict which drugs will work best for your recurrent or metastatic salivary gland cancer. You would need to provide a tumor sample and have adequate organ function.
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
This study collects blood and tumor tissue samples to analyze biological markers in patients with advanced head and neck squamous cell carcinoma before starting immunotherapy. The goal is to better understand how these markers relate to treatment response.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a new targeted drug (SYS6010) compared with standard single-drug treatments for advanced head and neck cancer that has not responded to previous therapies. The goal is to see if this new drug can shrink tumors or slow cancer growth better than the usual options.
This trial is for people with head and neck cancer that has not spread to distant parts of the body. It is a non-treatment study that will look at the molecular features of your tumor from a biopsy sample to help guide future treatment decisions.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.